Xilis is developing next-generation technologies to guide precision therapy for cancer patients and accelerate drug discovery and development. MOS^TM are microscale tumors that retain structure, genetic alterations, gene expression, immune microenvironment, and histopathology from individual patients. Our MOS platform enables rapid diagnostics for personalized therapy prioritization by predicting patient response, and scalable patient-derived models for high-throughput and immuno-oncology drug discovery.

The MOS^TM technology is transforming cancer drug development by providing an end-to-end patient centric solution. Our breakthrough platform provides cost-effective, high-throughput drug candidate screening, pre-clinical assessment of immuno-oncology drugs, personalized assays to determine patient eligibility for clinical trials, and companion diagnostics to guide patients to newly developed treatments.